DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07627074

Recruiting

Weight Loss in Adults Using Semaglutide (Real-world Study)

Real-world Weight Outcomes in Adults Treated With Semaglutide s.c. 1.0 mg or 1.7 mg for Weight Management: a Non-interventional Cohort Study

Lead sponsor

Novo Nordisk A/S

Asset

Semaglutide

GLP-1 agonist

Listed sites

2

Recruiting sites

2

Enrollment

35,000

estimated

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥27

Primary endpoints

•Body weight•Proportion of individuals achieving a clinically meaningful weight loss

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07627074
Org study IDNN9536-8874
Secondary IDU1111-1338-2016World Health Organization (WHO)

Timeline

Milestones

Study start2026-05-12estimated
Primary completion2026-06-01estimated
Study completion2026-06-01estimated
Study first posted2026-06-04actual
Last update posted2026-06-04actual

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

The study population comprises adults initiating semaglutide in routine clinical practice.

Inclusion criteria

•Initiation of semaglutide for weight management during the study period.
•Age more than or equal to (≥) 18 at treatment initiation
•Baseline body mass index (BMI) ≥27 and less than (<) 30 kilogram per meter square (kg/m^2) with at least one weight-related comorbidity, or BMI ≥30 kg/m^2.
•Other inclusion criteria as defined in the protocol are applicable.

Exclusion criteria

•Prior use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) based medication or other obesity management medication (OMMs).
•Bariatric surgery at baseline.
•Diabetes at baseline.
•Pregnancy at baseline.

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

3 endpoints
Primary/protocol endpoint

Change in body weight

Time frame:From index date (day 0) to week 68 (day 476)

change from baseline, improvement

Primary/protocol endpoint

Change in body weight

Time frame:From index date (day 0) to week 68 (day 476)

change from baseline, improvement

Primary/protocol endpoint

Proportion of individuals achieving a clinically meaningful weight loss

Time frame:From index date (day 0) to week 68 (day 476)

threshold achievement, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.